Themis Medicare Limited — Important, 14-02-2025: Financial Result Updates

The consolidated financial performance of Themis Medicare Limited indicates a robust growth trajectory for the quarter and nine months ending December 31, 2024. Total revenue reached ₹98.28 crore, reflecting a year-over-year increase of approximately 18% compared to ₹83.08 crore in the same period last year, driven by a rebound in demand and strategic market expansion.

Net profit for the period stood at ₹51.93 crore, contrasting with ₹73.68 crore from the previous year, impacted by increased operational costs. The earnings per share (EPS) now reflect at ₹0.06, a decline from ₹0.80, attributed to heightened employee benefit expenses and higher finance costs, which rose 12.35% year-over-year, reflecting the company's efforts to scale operations.

On the balance sheet, total expenses increased to ₹90.61 crore, substantially influenced by rising material costs and operational expenses, emphasizing a 12% uptick in cost management challenges. This suggests pressures on the company’s operational efficiency, which it must address moving forward.

Strategically, Themis Medicare is focusing on leveraging its pharmaceutical segment while managing costs more effectively. The outlook appears cautious yet optimistic, as the company prepares for upcoming developments, including a proposed sale of goods worth ₹250 crore to a related party, which may bolster revenue streams.

For investors, the current scenario suggests a hold strategy, with attention to cost control mechanisms and market conditions shaping future performance. The company's strategic decisions will be pivotal in enhancing profitability and addressing profitability challenges.